Bert Bammens

Bert Bammens

Auto-generated profile, based on publicly available information

Bert Bammens

Nephrology, University Hospitals Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2009 in Kidney International
Verified
Journal Article
Closed access
PEPieter Evenepoel
Pieter Evenepoel
Björn MeijersBjörn Meijers
Björn Meijers
BBBert R.M. Bammens
Bert R.M. Bammens
Kristin VerbekeKristin Verbeke
Kristin Verbeke

1 March 2006 in Kidney International
Verified
Journal Article
Closed access
PDF file
BBB. Bammens
B. Bammens
PEPieter Evenepoel
Pieter Evenepoel
HKH. Keuleers
H. Keuleers
Kristin VerbekeKristin Verbeke
Kristin Verbeke
YVY. Vanrenterghem
Y. Vanrenterghem

1 July 2010 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
Björn MeijersBjörn Meijers
Björn Meijers
KCKathleen Claes
Kathleen Claes
BBBert Bammens
Bert Bammens
HLHenriette de Loor
Henriette de Loor
LVLiesbeth Viaene
Liesbeth Viaene
PEPieter Evenepoel
Pieter Evenepoel
Background and objectives: Cardiovascular disease is highly prevalent in chronic kidney disease. Traditional risk factors are insufficient to explain the high cardiovascular disease prevalence. Free p-cresol serum concentrations, mainly circulating as its derivative p-cresyl sulfate, are associated with cardiovascular disease in hemodialysis patients. It is not known if p-cresol is associated with cardiovascular disease in patients with chronic kidney disease not yet on dialysis. Design, setting, participants, & measurements: In a prospective observational study in 499 patients with mild-to-moderate kidney disease, we examined the multivariate association between p-cresol free serum concentrations and cardiovascular events. Results: After a mean follow-up of 33 mo, 62 patients reached the primary end point of fatal or nonfatal cardiovascular events. Higher baseline concentrations of free p-cresol were directly associated with cardiovascular events (univariate hazard ratio [HR] 1.79, P < 0.0001). In multivariate analysis, p-cresol remained a predictor of cardiovascular events, independent of GFR and independent of Framingham risk factors (full model, HR 1.39, P = 0.04). Conclusions: These findings suggest that p-cresol measurements may help to predict cardiovascular disease risk in renal patients over a wide range of residual renal function, beyond traditional markers of glomerular filtration. Whether p-cresol is a modifiable cardiovascular risk factor in CKD patients remains to be proven.

1 May 2008 in Kidney International
Verified
Journal Article
Closed access
Björn MeijersBjörn Meijers
Björn Meijers
BBB. Bammens
B. Bammens
BMB. De Moor
B. De Moor
Kristin VerbekeKristin Verbeke
Kristin Verbeke
YVY. Vanrenterghem
Y. Vanrenterghem
PEPieter Evenepoel
Pieter Evenepoel

19 February 2004 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
PEPieter Evenepoel
Pieter Evenepoel
KCKathleen Claes
Kathleen Claes
DKDirk Kuypers
Dirk Kuypers
BMBart Maes
Bart Maes
BBBert Bammens
Bert Bammens
YVYves Vanrenterghem
Yves Vanrenterghem
Background. The natural history of parathyroid function after successful renal transplantation (RT) and the factors predisposing to persistent hyperparathyroidism (HPT) are not well established. A better knowledge of these data may be helpful in the development of algorithms for optimal surveillance and treatment of HPT after successful RT. Our aim was to evaluate the post-transplant natural history of parathyroid function and calcium metabolism in patients with a functional renal graft and to identify risk factors for persistent HPT. Methods. Charts of 1165 allograft kidney recipients transplanted between 1989 and 2000 were reviewed. Patients with an intact parathyroid hormone (iPTH) level available at the time of transplantation were identified. The charts of the latter patients were checked for a variety of demographic and clinical data, and all determinations of the iPTH concentration available since transplantation were recorded. Serum levels of calcium, phosphorus, alkaline phosphatases and creatinine, concurrently determined, were also registered. Results. After an initial fall, iPTH levels showed a slow but steady decline towards the upper normal limit. The prevalence of persistent HPT, defined as an iPTH level ≥2.5 times the upper normal limit or the need for parathyroidectomy following transplantation, remained stable at ∼17% up to 4 years after transplantation. Patients with persistent HPT had significantly elevated serum levels of iPTH, calcium and phosphorus at the time of RT, and had spent a longer time on dialysis. Post-transplant iPTH levels correlated significantly with transplant kidney function. Conclusion. Kidney transplant recipients with a high iPTH and calcium × phosphate product at the time of transplantation are at risk for persistent HPT especially when renal function is suboptimal. Therapy for persistent HPT, if considered, should be initiated 3 months post-transplantation since further spontaneous improvement of parathyroid function thereafter is limited.

7 November 2013 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MNMaarten Naesens
Maarten Naesens
LHLine Heylen
Line Heylen
ELEvelyne Lerut
Evelyne Lerut
KCKathleen Claes
Kathleen Claes
LWLiesbeth De Wever
Liesbeth De Wever
YVYves Vanrenterghem
Yves Vanrenterghem
The intrarenal resistive index is routinely measured in many renal-transplantation centers for assessment of renal-allograft status, although the value of the resistive index remains unclear. In a single-center, prospective study involving 321 renal-allograft recipients, we measured the resistive index at baseline, at the time of protocol-specified renal-allograft biopsies (3, 12, and 24 months after transplantation), and at the time of biopsies performed because of graft dysfunction. A total of 1124 renal-allograft resistive-index measurements were included in the analysis. All patients were followed for at least 4.5 years after transplantation. Allograft recipients with a resistive index of at least 0.80 had higher mortality than those with a resistive index of less than 0.80 at 3, 12, and 24 months after transplantation (hazard ratio, 5.20 [95% confidence interval {CI}, 2.14 to 12.64; P<0.001]; 3.46 [95% CI, 1.39 to 8.56; P=0.007]; and 4.12 [95% CI, 1.26 to 13.45; P=0.02], respectively). The need for dialysis did not differ significantly between patients with a resistive index of at least 0.80 and those with a resistive index of less than 0.80 at 3, 12, and 24 months after transplantation (hazard ratio, 1.95 [95% CI, 0.39 to 9.82; P=0.42]; 0.44 [95% CI, 0.05 to 3.72; P=0.45]; and 1.34 [95% CI, 0.20 to 8.82; P=0.76], respectively). At protocol-specified biopsy time points, the resistive index was not associated with renal-allograft histologic features. Older recipient age was the strongest determinant of a higher resistive index (P<0.001). At the time of biopsies performed because of graft dysfunction, antibody-mediated rejection or acute tubular necrosis, as compared with normal biopsy results, was associated with a higher resistive index (0.87±0.12 vs. 0.78±0.14 [P=0.05], and 0.86±0.09 vs. 0.78±0.14 [P=0.007], respectively). The resistive index, routinely measured at predefined time points after transplantation, reflects characteristics of the recipient but not those of the graft. (ClinicalTrials.gov number, NCT01879124.)